Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

被引:9
|
作者
Cortes-Selva, Diana [1 ]
Perova, Tatiana [1 ]
Skerget, Sheri [1 ]
Vishwamitra, Deeksha [1 ]
Stein, Sarah [1 ]
Boominathan, Rengasamy [1 ]
Lau, Onsay [1 ]
Calara-Nielsen, Karl [1 ]
Davis, Cuc [1 ]
Patel, Jaymala [1 ]
Banerjee, Arnob [1 ]
Stephenson, Tara [1 ]
Uhlar, Clarissa [1 ]
Kobos, Rachel [2 ]
Goldberg, Jenna [2 ]
Pei, Lixia [2 ]
Trancucci, Danielle [2 ]
Girgis, Suzette [1 ]
Lin, Shun Xin Wang [1 ]
Wu, Liviawati S. [3 ]
Moreau, Philippe [4 ]
Usmani, Saad Z. [5 ]
Bahlis, Nizar J. [6 ]
van de Donk, Niels W. C. J. [7 ]
Verona, Raluca I. [1 ]
机构
[1] Janssen Res & Dev, Spring House, PA USA
[2] Janssen Res & Dev, Raritan, NJ USA
[3] Janssen Res & Dev, South San Francisco, CA USA
[4] Univ Hosp Hotel Dieu, Nantes, France
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[7] Vrije Univ Amsterdam, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands
关键词
T-CELLS; BISPECIFIC ANTIBODY; PHASE-III; NAIVE; DEXAMETHASONE; DARATUMUMAB; EFFECTOR; OUTCOMES;
D O I
10.1182/blood.2023022823
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) x CD3 bispecific fi c antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (R/RMM). As a T-cell redirection therapy, clinical outcomes with teclistamab may be influenced fl uenced by patient immune fi tness and tumor antigen expression. We correlated tumor characteristics and baseline immune profiles fi les with clinical response and disease burden in patients with R/RMM from the pivotal phase 1/2 MajesTEC-1 study, focusing on patients treated with 1.5 mg/kg of teclistamab (N =165). Peripheral blood samples were collected at screening, and bone marrow samples were collected at screening and cycle 3. Better clinical outcomes to teclistamab correlated with higher baseline total T-cell counts in the periphery. In addition, responders (partial response or better) had a lower proportion of immunosuppressive regulatory T cells (Tregs), T cells expressing coinhibitory receptors (CD38, PD-1, and PD-1/TIM-3), and soluble BCMA and a T-cell profile fi le suggestive of a more cytolytic potential, compared with nonresponders. Neither frequency of baseline bone marrow BCMA expression nor BCMA-receptor density was associated with clinical response to teclistamab. Improved progression-free survival was observed in patients with a lower frequency of T cells expressing exhaustion markers and immunosuppressive Tregs. Overall, response to teclistamab was associated with baseline immune fi tness; nonresponders had immune profiles fi les suggestive of immune suppression and T-cell dysfunction. These fi ndings illustrate the importance of the contribution of the immune landscape to T-cell redirection therapy response. This trial was registered at www.ClinicalTrials.gov as #NCT03145181/ NCT04557098.
引用
收藏
页码:615 / 628
页数:14
相关论文
共 50 条
  • [21] Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Nooka, Ajay
    van de donk, Niels
    Moreau, Philippe
    Bhutani, Manisha
    Oriol, Albert
    Martin, Thomas
    Rosinol, Laura
    Mateos Manteca, Maria-Victoria
    Bahlis, Nizar J.
    Garfall, Alfred
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Huang, Lin
    Vishwamitra, Deeksha
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S80 - S80
  • [22] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study (vol 130, pg 886, 2024)
    Nooka, A. K.
    Rodriguez, C.
    Mateos, M., V
    CANCER, 2024, 130 (17) : 3046 - 3046
  • [23] Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
    Martin, Thomas G.
    Moreau, Philippe
    Usmani, Saad Z.
    Garfall, Alfred
    Mateos, Maria -Victoria
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Krishnan, Amrita
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Delforge, Michel
    Trancucci, Danielle
    Pei, Lixia
    Kobos, Rachel
    Fastenau, John
    Gries, Katharine S.
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 194 - 202
  • [24] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
  • [25] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Moreau, Philippe
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Lin, Shun X. W.
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    Usmani, Saad Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 495 - 505
  • [26] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
    Rosinol, Laura
    Garfall, Alfred
    Benboubker, Lotfi
    Uttervall, Katarina
    Groen, Kaz
    van de Donk, Niels
    Matous, Jeffrey
    Vishwamitra, Deeksha
    Hodin, Caroline
    Stephenson, Tara
    Qi, Keqin
    Zuppa, Athena
    Chastain, Katherine
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85
  • [27] Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
    Costa, Luciano J.
    Bahlis, Nizar J.
    Usmani, Saad Z.
    van de Donk, Niels W. C. J.
    Nooka, Ajay K.
    Perrot, Aurore
    Qi, Keqin
    Hodin, Caroline
    Uhlar, Clarissa
    Zuppa, Athena
    Chastain, Katherine
    Doyle, Margaret
    Maria-Victoria, Mateos
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S546 - S547
  • [28] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosino, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martínez-López, Joaquín
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca I.
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa M.
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita Y.
    BLOOD, 2021, 138
  • [29] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Popat, Rakesh
    Usmani, Saad Z.
    Garfall, Alfred
    van de Donk, Niels
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Moreau, Philippe
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36
  • [30] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
    Cohen, Yael C.
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Chu, Michael P.
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia A.
    Kumar, Ashwini
    Krevvata, Maria
    Peterson, Michelle R.
    Di Scala, Lilla
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos, Maria-Victoria
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149